The drama at JAMA that began with Jonathan Leo asking the journal to look into Robert Robinson's ties to Forest Laboratories (Robinson published a paper in JAMA saying that Lexapro helped prevent depression in stroke victims) is continuing. Not only has Leo heard back from the JAMA editors after publishing a letter in the British Medical Journal, Robinson now has a few things of his own to say. Also in BMJ, Robinson, who is at Carver College of Medicine, suggests that Leo is "on an ideologically based mission" since Leo was a board member of the International Center for the Study of Psychiatry and Psychology, a group that Robinson says is against the use of psychiatric medicine. The ICSPP's website says, "We are not against the use of psychoactive drugs by competent adults who have been thoroughly informed of their value, potential side effects, and alternatives." Leo tells the WSJ Health blog that he resigned from the ICSPP board two years ago and that he isn't against all psychiatric medications.
JAMA Drama Continues
Apr 16, 2009